Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan to Start Global Phase III Trial of Lead Cancer Drug

publication date: Apr 25, 2017
Aslan Pharma of Singapore will start a global Phase III trial of its lead drug candidate, varlitinib, in patients with biliary tract cancer. The US FDA recently approved Aslan’s Investigational New Drug application for the drug, a small molecule pan-HER inhibitor. The two-arm trial, which will enroll 120 patients at 60 sites around the world, will be led by Milind Javle, MD, an expert in biliary tract cancer from Houston's MD Anderson Cancer Center. No treatments for biliary tract cancer are currently approved. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital